May 2023: BioAegis Therapeutics to Sponsor a Webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases

Webinar will take place Tuesday, May 23, 2023 at 2:00 PM Eastern Time

NORTH BRUNSWICK, N.J., May 10, 2023 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical-stage company developing novel therapies for inflammatory diseases through a portfolio built around plasma gelsolin (pGSN), a highly conserved and abundant endogenous human immune regulatory protein, announces that it will host a free webinar on the expanding spectrum of auto- and hyper- inflammatory diseases on Tuesday, May 23, 2023 at 2:00 pm Eastern Time.

The webinar, Below the Eyes of the Hippopotamus: The Expanding Spectrum of Auto- and Hyper- Inflammatory Diseases will delve beneath the surface of this rapidly growing field of auto-inflammatory and hyper-inflammatory diseases. It will explore what we know and will need to know moving forward, in particular:

  • How these diseases of the innate immune system are identified and categorized, and the danger of the cytokine storm.
  • The major scientific breakthrough in identifying genes responsible for autoinflammatory diseases and related genotypes.
  • Key biomarkers for autoinflammatory diseases and new targets for treatments, like the NLRP3 inflammasome.

A live Q&A discussion with key opinion leader, David Fajgenbaum, MD, will follow the presentation.  Please click here to register.

The webinar will feature Lester Kobzik, MD, Chief Medical Officer, Cellecta, Inc., Mark J. DiNubile, MD, FIDSA, Chief Medical Officer, BioAegis Therapeutics, and David Fajgenbaum, MD, MBA, MSc, co-Founder & President of the Castleman Disease Collaborative Network.

Speaker Biographies
Lester Kobzik, MD is a professor emeritus of Pathology at the Harvard Medical School and the Harvard T. H. Chan School of Public Health. His research interests center on lung disease and how the lung defends itself against inhaled toxic and infectious challenges. His work has characterized scavenger receptors on lung macrophages and how they function to remove potentially harmful if inhaled particulates and bacteria. He is also actively engaged in studies of infectious agents, including use of functional genomic screening to identify novel pathways and therapeutic leads. He has authored over 300 research publications in the area of lung pathobiology and has served on numerous grant and scientific review panels for the NIH, EPA and other research organizations.

Dr. Kobzik received his undergraduate degree and medical degree from Tufts University. He completed residency training in anatomic pathology at the Brigham and Women’s Hospital, then joined the faculty there and at the Harvard Medical and Public Health Schools. Dr. Kobzik currently serves as Chief Scientific Advisor for BioAegis Therapeutics.

Mark J. DiNubile, MD, FIDSA is a board-certified physician in Internal Medicine and the subspecialty of Infectious Diseases and Fellow of the Infectious Disease Society of America (FIDSA). Prior to joining BioAegis in 2017, Dr. DiNubile spent 16 years at Merck & Co., Inc. where he was primarily focused on the therapeutic areas of Infectious Diseases and Vaccines. He has extensively published on a diverse spectrum of medical and scientific topics.

Dr. DiNubile graduated from the University of Pennsylvania summa cum laude and Yale School of Medicine, followed by internship and residency at the Hospital of the University of Pennsylvania.  As a fellow at Harvard Medical School, he completed his clinical infectious diseases requirements at Brigham & Women’s Hospital followed by hematology research focusing on neutrophil motility and phagocytosis at the Massachusetts General Hospital. For more than a decade, prior to joining industry at Merck, Mark cared for patients in the ambulatory and hospital setting; taught medical students, house officers and fellows; chaired the hospital Pharmacy and Therapeutics Committee; initiated an antibiotic-stewardship program; and pursued clinical investigation and basic research, largely related to host defense and immunosuppression.

David Fajgenbaum, MD, MBA, MSc, is a physician-scientist at the University of Pennsylvania, co-Founder & President of the Castleman Disease Collaborative Network, and founding director of the Center for Cytokine Storm Treatment and Laboratory. He is also the national bestselling author of “Chasing My Cure: A Doctor’s Race to Turn Hope Into Action”.  Dr. Fajgenbaum is also a patient battling a deadly disease which he discovered a treatment for that is saving his life and others. Through his work at Penn, he has identified and advanced 11 other treatments for autoimmunity and cancer. He recently co-founded Every Cure, a non-profit on a mission to unlock the full potential of FDA-approved medicines to treat every disease possible. He has been profiled by The NY Times, TODAY, GMA, and others and received numerous awards including the 2016 Atlas Award along with then VP Joe Biden and Forbes 30 Under 30. Dr. Fajgenbaum earned a BS from Georgetown University, MSc from the University of Oxford, MD from the University of Pennsylvania, and MBA from The Wharton School. 

 About BioAegis
BioAegis Therapeutics Inc. is a NJ-based clinical-stage, private company whose mission is to capitalize on a key component of the body’s innate immune system, plasma gelsolin, to prevent adverse outcomes in diseases driven by inflammation and infection.

BioAegis’ platform is built upon the recombinant form of plasma gelsolin, a highly conserved abundant human protein in healthy individuals. Its role is to keep inflammation localized to the site of injury and to boost the body’s ability to clear pathogens, but normal levels are depleted by diverse inflammatory conditions. Restoring gelsolin levels with the human recombinant form, rhu-pGSN, helps immune cells fight infection and controls inflammation so it does not spread and cause damage. Rhu-pGSN is a non-antibiotic, host-directed, non-immunosuppressive treatment for inflammation due to both infectious and non-infectious causes.

BioAegis has the exclusive license to broad, worldwide intellectual property through Harvard-Brigham and Women’s Hospital. It holds over 40 patents issued for coverage of inflammatory disease, infection, renal failure, and neurologic disease. BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

Investor Inquiries:
Steven Cordovano

Media Inquiries:
Christine Lagana

This press release contains express or implied forward-looking statements, which are based on current expectations of management.  These statements relate to, among other things, our expectations regarding management’s plans, objectives, and strategies.  These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements.  BioAegis assumes no obligation to update any forward-looking statements appearing in this press release in the event of changing circumstances or otherwise, and such statements are current only as of the date they are made.